Die Informationen auf den nächsten Seiten dürfen nur medizinischen Fachkreisen zugänglich gemacht werden (Heilmittelwerbegesetz). Sie haben die Möglichkeit sich sowohl über den Bayer Vital Login als auch über DocCheck einzuloggen.

Sollten Sie noch bei keinem dieser Services registriert sein, melden Sie sich bitte dort an. Es warten noch viele weitere interessante Artikel und Services auf Sie.

3.10 BETAPAEDIC-Studie

Interferon beta-1b in treatment-naïve paediatric patients with relapsing–remitting multiple sclerosis: Two-year results from the BETAPAEDIC study

Auszug aus der Publikation von Gärtner J et al., MSJ 2017; DOI: 10.1177/2055217317747623.

Abstract

Background and objective

Study evaluating Betaferon's safety and tolerability in paediatric patients with multiple sclerosis (BETAPAEDIC) is a prospective, open-label observational multicentre study to assess the safety and effectiveness of interferon beta-1b in paediatric patients with relapsing-remitting multiple sclerosis.

Methods

Treatment-naïve patients (12–16 years) scheduled to start interferon beta-1b were enrolled with follow-up visits every six months for two years. Effectiveness was evaluated by annualised relapse rate, Expanded Disability Status Scale progression, cranial magnetic resonance imaging and cognitive testing. Fatigue was assessed by the Fatigue Severity Scale.

Results

Sixty-eight patients were screened and 67 enrolled, with mean (standard deviation) age 14.2 (1.3) years (n=65 in the effectiveness analysis). Mean disease duration was 11 months before study enrollment; at baseline, mean (standard deviation) Expanded Disability Status Scale was 0.6 (1.0); T2 lesion number 18.3 (15.1). Mean annualised relapse rate during the study was 0.7 (n=57), 28/57 patients (49.1%) had no relapses and for 40/52 (76.9%) no Expanded Disability Status Scale progression was observed; 23/56 (41.1%) were relapse- and progression-free to last follow-up. Neuropsychological test and fatigue scores were within normal ranges (baseline and last follow-up). Eighteen patients had fatigue at some point. New T2 and gadolinium-enhancing (Gd+) lesions were seen in 43/55 (66.2%) and 29/55 (52.7%) patients respectively. Most frequent adverse events were influenza-like illness, headache, injection-site reactions and elevated liver enzymes.

Conclusion

Interferon beta-1b is an effective treatment with a favorable safety profile for paediatric patients.

Literatur
  1. Banwell, B, Ghezzi, A, Bar-Or, A. Multiple sclerosis in children: Clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007; 6: 887–902. Google Scholar, Crossref, Medline
  2. MacAllister, WS, Boyd, JR, Holland, NJ. The psychosocial consequences of pediatric multiple sclerosis. Neurology 2007; 68: S66–S69. Google Scholar, Crossref, Medline
  3. Gorman, MP, Healy, BC, Polgar-Turcsanyi, M. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009; 66: 54–59. Google Scholar, Crossref, Medline
  4. Renoux, C, Vukusic, S, Mikaeloff, Y. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007; 356: 2603–2613. Google Scholar, Crossref, Medline
  5. Amato, MP, Ponziani, G, Siracusa, G. Cognitive dysfunction in early-onset multiple sclerosis: A reappraisal after 10 years. Arch Neurol 2001; 58: 1602–1606. Google Scholar, Crossref, Medline
  6. Banwell, BL, Anderson, PE. The cognitive burden of multiple sclerosis in children. Neurology 2005; 64: 891–894. Google Scholar, Crossref, Medline
  7. Rao, SM, Leo, GJ, Bernardin, L. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41: 685–691. Google Scholar, Crossref, Medline
  8. Chitnis, T, Tenembaum, S, Banwell, B. Consensus statement: Evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler 2012; 18: 116–127. Google Scholar, Link
  9. Huppke, P, Gartner, J. A practical guide to pediatric multiple sclerosis. Neuropediatrics 2010; 41: 157–162. Google Scholar, Crossref, Medline
  10. Adams, AB, Tyor, WR, Holden, KR. Interferon beta-1b and childhood multiple sclerosis. Pediatr Neurol 1999; 21: 481–483. Google Scholar, Crossref, Medline
  11. Banwell, B, Reder, AT, Krupp, L. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006; 66: 472–476. Google Scholar, Crossref, Medline
  12. Mikaeloff, Y, Moreau, T, Debouverie, M. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr 2001; 139: 443–446. Google Scholar, Crossref, Medline
  13. Petermann, F and, Petermann, U. HAWIK-IV, Hamburg-Wechsler-Intelligenztest fur Kinder-IV, Adaptation of WISC-IV, David Wechsler, Harcourt Assesment, 2003; Manual, Hans Huber. Bern: Hogrefe AG, 2007. Google Scholar
  14. Wechsler, D. Wechsler Intelligence Scale for Children – Manual. 4th ed. London: Harcourt Assessment, 2004. Google Scholar
  15. Horn, R. Standard Progressive Matrices (SPM-C/SPM-P/SPM-Plus). Frankfurt: Pearson, 2009. Google Scholar
  16. Brickenkamp, R and, Zillmer, E. d2 Test of Attention Manual. 1st ed. Seattle, Toronto, Bern, Goettingen: Hogrefe & Huber, 2002. Google Scholar
  17. Brickenkamp, R. Test d2, Aufmerksamkeits-Belastungs-Test Manual. 9th ed. Gottingen: Hogrefe, 2002. Google Scholar
  18. Beery, KE and, Beery, NA. The Beery–Buktenica Developmental Test of  Visual–Motor  Integration: Administration, Scoring, and Teaching manual. 6th ed. Minneapolis: Pearson, 2010. Google Scholar
  19. Simone, M, Chitnis, T. Use of disease-modifying therapies in pediatric MS. Curr Treat Options Neurol 2016; 18: 36. Google Scholar, Crossref, Medline
  20. Reder, AT, Oger, JF, Kappos, L. Short-term and long-term safety and tolerability of interferon beta-1b in multiple sclerosis. Mult Scler Relat Disorders 2013; 3: 294–302. Google Scholar, Crossref, Medline
  21. Ghezzi, A, Amato, MP, Makhani, N. Pediatric multiple sclerosis: Conventional first-line treatment and general management. Neurology 2016; 87: S97–S102. Google Scholar, Crossref, Medline

Gärtner J et al., MSJ 2017; DOI: 10.1177/2055217317747623

 

Nähere Informationen zum Thema „MS und Kinder/ Betaferon und Kinder“ finden Sie in Kapitel 5